TY - JOUR
T1 - Construction and characterization of recombinant human C9 or C7 linked to single Chain Fv directed to CD25
AU - Raitses Gurevich, Maria
AU - Fishelson, Zvi
N1 - Funding Information:
This research was supported in part by grants from the Israel Science Foundation and the US-Israel Binational Science Foundation .
PY - 2013/10
Y1 - 2013/10
N2 - Complement-dependent cytotoxicity (CDC) is a potent promoter of tumor clearance during monoclonal antibody therapy. Complement activation on antibody-bearing tumor cells results in formation of the membrane attack complex (MAC), which activates cell death. The complement activation cascade that bridges between antibody binding and MAC formation is regulated by complement inhibitors that are over-expressed on tumor cells. In order to bypass those complement regulators, we have designed an immunoconjugate composed of a humanized single chain Fv of an anti-Tac (CD25) monoclonal antibody fused at its C terminus either to complement protein C9 (scFv-C9) or to complement C7 (scFv-C7) and tagged with six histidines at the C terminal end. Recombinant scFv-C9 and scFv-C7 were expressed in 293T cells and purified. Both are shown to efficiently bind to CD25-positive tumor cells. In addition, scFv-C9, but not scFv-C7, increases MAC deposition on the cells and enhances complement-mediated cell death of target CD25-positive cells. Thus, scFv-C9 fusion protein is potentially a novel reagent for application in cancer immunotherapy.
AB - Complement-dependent cytotoxicity (CDC) is a potent promoter of tumor clearance during monoclonal antibody therapy. Complement activation on antibody-bearing tumor cells results in formation of the membrane attack complex (MAC), which activates cell death. The complement activation cascade that bridges between antibody binding and MAC formation is regulated by complement inhibitors that are over-expressed on tumor cells. In order to bypass those complement regulators, we have designed an immunoconjugate composed of a humanized single chain Fv of an anti-Tac (CD25) monoclonal antibody fused at its C terminus either to complement protein C9 (scFv-C9) or to complement C7 (scFv-C7) and tagged with six histidines at the C terminal end. Recombinant scFv-C9 and scFv-C7 were expressed in 293T cells and purified. Both are shown to efficiently bind to CD25-positive tumor cells. In addition, scFv-C9, but not scFv-C7, increases MAC deposition on the cells and enhances complement-mediated cell death of target CD25-positive cells. Thus, scFv-C9 fusion protein is potentially a novel reagent for application in cancer immunotherapy.
KW - C7
KW - C9
KW - CD25
KW - Complement
KW - ScFv
UR - http://www.scopus.com/inward/record.url?scp=84877598752&partnerID=8YFLogxK
U2 - 10.1016/j.molimm.2013.03.013
DO - 10.1016/j.molimm.2013.03.013
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
AN - SCOPUS:84877598752
SN - 0161-5890
VL - 55
SP - 400
EP - 408
JO - Molecular Immunology
JF - Molecular Immunology
IS - 3-4
ER -